Bayer Licenses PRMT5 inhibitor From Suzhou Puhe BioPharma

Bayer (BAYRY) announced a licensing agreement with Suzhou Puhe BioPharma Co., a clinical-stage biotechnology company.Suzhou Puhe BioPharma is focused on the research and development of innovative small-molecule precision therapeutics.The companies have collaborated for Suzhou Puhe BioPharma’s oral, small molecule protein arginine N-methyltransferase 5 (PRMT5) inhibitor that selectively targets methylthioadenosine phosphorylase (MTAP)-deleted tumors.Under the agreement, Bayer obtained an exclusive worldwide ...